VA
AXSM icon

Vident Advisory’s Axsome Therapeutics AXSM Stock Holding History

Vident Advisory’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$544K Buy
2,223
+124
+6% +$26.9K ﹤0.01% 1317
2026
Q1 		$355K Buy
2,099
+422
+25% +$72.9K ﹤0.01% 1419
2025
Q4 		$306K Sell
1,677
-280
-14% -$39.1K ﹤0.01% 1364
2025
Q3 		$238K Buy
+1,957
New +$220K ﹤0.01% 1504
2025
Q2 		– Sell
-3,083
Closed -$360K – 1608
2025
Q1 		$360K Buy
+3,083
New +$351K 0.01% 1195

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vident Advisory's AXSM Position: Q2 2026 in Review

Vident Advisory increased its Axsome Therapeutics (AXSM) stake by 5.9% in Q2 2026, buying an estimated $26.9K and bringing the position to 2,223 shares worth $544K. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

Vident Advisory first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Vident Advisory held 2,223 shares of Axsome Therapeutics worth $544K as of Q2 2026.
  • Vident Advisory bought 124 Axsome Therapeutics shares in Q2 2026, an estimated $26.9K.
  • Axsome Therapeutics made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1317 holding.
  • Vident Advisory first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.